Ad
related to: grail illumina news today breaking news
Search results
Results From The WOW.Com Content Network
September 3, 2024 at 7:32 AM. By Foo Yun Chee. BRUSSELS (Reuters) -U.S. gene sequencing company Illumina on Tuesday won its court fight against the European Union's investigation of its $7.1 ...
The EU competition enforcer subsequently blocked the $7.1 billion deal in 2022 on concerns that Illumina would have an incentive to stop Grail's rivals from accessing its technology to develop ...
The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in ...
Grail, valued at $7.1 billion under Illumina's deal, is seeking to market a blood test that can diagnose many kinds of cancer, known as a liquid biopsy. Illumina had spun off Grail in 2016 but ...
grail.com. GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. [3] Grail was spun-out from Illumina on June 24, 2024. Their liquid biopsy (also called multi-cancer ...
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and ...
Shareholders will receive one common share of Grail for every six shares of Illumina, which will retain a 14.5% stake in the unit after the spinoff on June 24. Shares of Illumina were up 4% in ...
The U.S. life sciences company had completed its $7.1 billion takeover of Grail in August 2021, without securing the EU regulatory approval. The European Commission ordered Illumina last December ...